Search for: ""Wyeth v. Levine" OR "555 U.S. 555"" Results 61 - 74 of 74
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
22 Aug 2014, 9:22 am
Levine, 555 U.S. 555 (2009), impossibility preemption did not apply to innovator prescription drugs because simultaneous compliance with FDA and state tort law labeling obligations was possible due to the “changes being effected” (“CBE”) exception allowing updated warnings without prior FDA approval. [read post]
22 Mar 2013, 10:36 am by Bexis
Levine, 555 U.S. 555, 565 (2009) (considering only the “narrower question” of “an adequate warning” claim; avoiding preemption of a “duty to contraindicate”); PLIVA v. [read post]
5 Sep 2013, 12:24 pm by Bexis
Levine, 555 U.S. 555 (2009) – we took a look.Hmmmm.For a post-Levine decision, we actually don’t think the rulings are all that bad. [read post]
6 Jun 2012, 5:35 am by Bexis
Levine, 555 U.S. 555 (2009), that the defendant could have “strengthened” the labeling by making the label “more prominent” generally. [read post]
29 Dec 2011, 6:53 am by Bexis
Levine, 555 U.S. 555 (2009), a lot of commentators had written generic preemption off – but not us, as we pointed out here almost a month before Mensing was decided. [read post]
7 Jul 2011, 2:31 pm by Bexis
Wyeth-Ayerst Laboratories, 385 F.3d 961 (6th Cir. 2004)), with jurisdiction over Michigan – yet another court out of New York now presumes to know New Jersey law better than the New Jersey courts (McDarby v. [read post]
7 May 2012, 5:00 am by Bexis
Levine, 555 U.S. 555 (2009), involved warning claims (again, they’re the most common), neither case was 100% on point.Bartlett initially demonstrates why “design defect” simply doesn’t fit prescription drugs (some medical devices are different). [read post]